Adaptive design of VALOR, a phase III trial of vosaroxin or placebo in combination with cytarabine for patients with first relapsed or refractory acute myeloid leukemia.


Conference Paper

Full Text

Duke Authors

Cited Authors

  • Mehta, CR; Michelson, G; Salganik, M; Feaster, J; Allen, R; Cahill, AL; Fox, JA; Ketchum, SB; Ravandi, F; Erba, HP; Schiller, GJ; Stuart, RK; Vey, N; Feldman, EJ

Published Date

  • May 20, 2011

Published In

Volume / Issue

  • 29 / 15_suppl

Start / End Page

  • TPS201 - TPS201

Published By

Electronic International Standard Serial Number (EISSN)

  • 1527-7755

International Standard Serial Number (ISSN)

  • 0732-183X

Digital Object Identifier (DOI)

  • 10.1200/jco.2011.29.15_suppl.tps201